MONMOUTH JUNCTION, N.J., Nov. 25 /PRNewswire/ -- TYRX, Inc., a leader in the development and commercialization of convergent drug-device products, announced today the 1,000th implant of the AIGISRx(TM) Anti-bacterial Envelope following its commercialization in June, 2008. AIGISRx is an anti-bacterial surgical mesh developed to deliver anti-microbial agents that help provide protection against infections associated with implanted pacemakers and cardioverter defibrillators.

Dr. David Delurgio, Director of Electrophysiology Services, Crawford Long of Emory University Hospital, Atlanta, GA, implanted the 1,000th AIGISRx in a 61 year old female who received a replacement bi-ventricular pacemaker. Dr. Delurgio placed the pacemaker into the AIGISRxAnti-bacterial Mesh and positioned the device normally within the surgically created pocket. Once implanted, AIGISRxprovides an adjunct to general antibiotic therapy by providing localized antibiotic therapy from the antibiotics minocycline and rifampin.

"AIGISRx represents a significant advance in possibly protecting our patients from current and emerging infections, representing the majority of organisms implicated in 'pocket infections' following the implantation of pacemakers or cardioverter defibrillators," stated Dr. Delurgio. "The demonstrated benefits of AIGISRx may prove to be cost-effective by potentially preventing serious and life-threatening infections, including those caused by superbugs such as MRSA. AIGISRx Anti-bacterial Mesh protects against this risk by providing localized antibiotics as an adjunct to normal antibiotic therapy," added Dr. Delurgio.

"Achieving this significant milestone is a testament to the demand for a product that has the potential to reduce infections and potential adverse events," said Bill Edelman, CEO of TYRX, Inc. "Because AIG
'/>"/>